Fresenius and WuXi Biologics enter exclusive development agreement to expand biosimilars pipeline

The Quick Take
Exclusive option rights for up to 37 potential first-to-market biosimilar candidates to significantly expand Fresenius' portfolio from 29 marketed and pipeline molecules today to up to 66 in the next decade, addressing more than €370 billion in originator sales; the largest development...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Aosom Kicks Off Black Friday 2026 with Its Biggest Discounts of the Year and Limited-Time Flash Deals
LONDON, PARIS and HAMBURG, Germany, Nov. 2, 2026 /PRNewswire/ -- As the year-end shopping season approaches, Aosom will kick off its 2026 Black Friday…
Business
Small businesses face these common hurdles - Boston Herald
Small businesses face these common hurdles Boston Herald
Business
Citizens reiterates Amentum stock rating on Sellafield contract win
Business
